TILT Subsidiary Jupiter Research to Develop and Supply Custom Pod Vaporizer for Curaleaf International – TILT Holdings (OTC:TLLTF)


Jupiter Research LLC, a 100% subsidiary of TILT Holdings Inc. TLLTF INCLINE entered a five-year exclusive manufacturing, supply and distribution agreement with Curaleaf International Limited CURVE to bring the fabricated Jupiter what liquid vaporizer to new territories overseas, for use as a medical device with extracts developed by Curaleaf International, subject to obtaining regulatory approvals in the relevant territories.

Introduced in 2020, the Liquid Que vaporizer is the first independent pod system made by Jupiter Research. Featuring a snap-on pod cartridge, magnetic connection, and refillable power supply, the Liquid Que’s design preserves the integrity of high-viscosity extracts at every step.

Jupiter Research will be Curaleaf International’s exclusive supplier of all vaping hardware, cartridges and related accessories, including the Liquid Que, for use with liquid medical cannabis products, initially bringing it to the UK and around the world. European Union, with other territories such as Switzerland, Norway, Australia, Israel and the United Arab Emirates will follow.

Curaleaf International will in turn develop each market, coordinate the approval of formulations and extracts in each territory in accordance with local regulations, and distribute the approved Liquid Que device in those markets exclusively. The Liquid Que is expected to reach the UK at the end of 2023.

price action

TILT titles the shares were trading up 9.58% at $0.1052 per share at the time of writing on Wednesday morning.

Get your daily dose of cannabis news on Benzinga Cannabis. Don’t miss any important developments in the industry.

Photo: Benzinga; Sources: Courtesy of geralt, lindsayfox via Pixabay

Related News

Ricky Williams’ Highsman is coming to this state via a partnership with TILT

TILT Launches CCELL’s New EVO Via Jupiter Research and Amends Facilities Purchase and Sale Agreement with IIPR

Source link

Comments are closed.